FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
+17.61%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$835M
AUM Growth
+$835M
(-9.3%)
Cap. Flow
+$43.7M
Cap. Flow
% of AUM
5.23%
Top 10 Holdings %
Top 10 Hldgs %
98.18%
Holding
15
New
2
Increased
2
Reduced
5
Closed
2
Top Buys
| 1 |
Pharvaris
PHVS
|
$91.3M |
| 2 |
Aclaris Therapeutics
ACRS
|
$61.7M |
| 3 |
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
|
$3.38M |
| 4 |
Kura Oncology
KURA
|
$1.19M |
Top Sells
| 1 |
Nurix Therapeutics
NRIX
|
$34.5M |
| 2 |
Generation Bio
GBIO
|
$24.3M |
| 3 |
Olema Pharmaceuticals
OLMA
|
$14.1M |
| 4 |
ALX Oncology
ALXO
|
$13.8M |
| 5 |
Cytokinetics
CYTK
|
$12.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $301M | 36.1% | 9,671,643 | – | – |
|
|
2
Pharvaris
PHVS
$1.39B
| $91.3M | 10.93% | +3,261,926 | New | +$91.3M |
|
|
3
Aclaris Therapeutics
ACRS
$209M
| $85.7M | 10.26% | 3,399,034 +2,447,650 | +257% | +$61.7M |
|
4
Keros Therapeutics
KROS
$618M
| $85.1M | 10.19% | 1,382,641 -30,064 | -2% | -$1.85M |
|
5
Relay Therapeutics
RLAY
$619M
| $74M | 8.86% | 2,139,380 | – | – |
|
|
6
ALX Oncology
ALXO
$62.7M
| $58M | 6.94% | 785,945 -187,569 | -19% | -$13.8M |
|
|
7
Kura Oncology
KURA
$686M
| $52.3M | 6.26% | 1,849,947 +41,965 | +2% | +$1.19M |
|
|
8
Nurix Therapeutics
NRIX
$714M
| $38.5M | 4.61% | 1,238,456 -1,109,348 | -47% | -$34.5M |
|
|
9
Cytokinetics
CYTK
$4.23B
| $20.5M | 2.46% | 881,901 -554,091 | -39% | -$12.9M |
|
|
10
Olema Pharmaceuticals
OLMA
$375M
| $13M | 1.56% | 393,030 -425,000 | -52% | -$14.1M |
|
|
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
| $8.11M | 0.97% | 1,787,094 | – | – |
|
|
PNT
12
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $3.68M | 0.44% | 350,000 | – | – |
|
|
DBTX
13
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $3.38M | 0.41% | +297,711 | New | +$3.38M |
|
|
14
Generation Bio
GBIO
$40.4M
| – | – | -857,939 | Closed | -$24.3M |
|
15
Vaxcyte
PCVX
$4B
| – | – | -465,821 | Closed | -$12.4M |
|